1. Home
  2. RES vs XERS Comparison

RES vs XERS Comparison

Compare RES & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RPC Inc.

RES

RPC Inc.

HOLD

Current Price

$5.73

Market Cap

1.5B

Sector

Energy

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$7.43

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RES
XERS
Founded
1984
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
RES
XERS
Price
$5.73
$7.43
Analyst Decision
Hold
Buy
Analyst Count
5
6
Target Price
$5.64
$10.83
AVG Volume (30 Days)
1.5M
1.6M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
2.02%
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.01
Revenue
$41,919,000,000.00
$49,590,000.00
Revenue This Year
$3.29
$34.37
Revenue Next Year
$4.05
$22.86
P/E Ratio
$45.40
$720.00
Revenue Growth
2216.21
142.67
52 Week Low
$4.18
$4.52
52 Week High
$8.16
$10.08

Technical Indicators

Market Signals
Indicator
RES
XERS
Relative Strength Index (RSI) 28.17 73.45
Support Level $5.19 $7.27
Resistance Level $5.76 $8.43
Average True Range (ATR) 0.32 0.26
MACD -0.10 0.08
Stochastic Oscillator 5.52 95.56

Price Performance

Historical Comparison
RES
XERS

About RES RPC Inc.

RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. Its operating segment includes Technical Services and Support Services. The Technical Services segment, which generates maximum revenue, comprises service lines that generate revenue based on equipment, personnel, or materials at the well site and are closely aligned with completion and production activities of the customers. The Support Services segment comprises service lines that generate revenue from services and equipment offered off the well site and are closely aligned with the customers' drilling activities.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: